TG THERAPEUTICS, INC. (TGTX) Stock
TGTX has an Alpha Score of 69 out of 100 (moderate), computed on Nov 7, 2026 from 3 of 4 sub-scores. 9 of the hedge funds AlphaScala tracks reported TGTX in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is D.E. Shaw's at $186.84M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 9, 2026. Its trailing P/E ratio is 20.1 and its net margin 55.2% (key statistics as of Nov 7, 2026).
What is TGTX's Alpha Score?
How it works →Alpha Score of 69 reflects moderate overall profile with strong momentum, weak value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 7, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own TGTX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 3.40M | $186.84M | +476% |
| Renaissance Technologies Jim Simons (founder) | 679K | $37.32M | +99% |
| Citadel Ken Griffin | 537K | $29.51M | -72% |
| Bridgewater Associates Ray Dalio | 430K | $23.62M | +38% |
| Millennium Management Israel Englander | 273K | $14.97M | +122% |
| Point72 Steve Cohen | 265K | $14.56M | NEW |
| Hussman Investment Trust John Hussman | 53K | $2.93M | n/a |
| Blackstone | 7K | $406.8K | NEW |
| Marshall Wace | 6K | $316.3K | -78% |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are TG THERAPEUTICS, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 10, 26 | Charney Laurence N | Director | SELL | 5.0K | $275K |
SEC Form 4 filings as of Nov 9, 2026
See cluster-buy signals across all tickers →What are TGTX's key statistics?
Key statistics as of Nov 7, 2026
How does TGTX's valuation compare with the Healthcare sector?
| Metric | TGTX | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 20.1 | 29.7 | 114 |
| Net margin | 55.22% | 3.62% | 174 |
| Return on equity | 72.30% | 2.96% | 200 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 10, 2026). P/E excludes loss-making companies.
TGTX price chart
Powered by TradingViewWhat does TG THERAPEUTICS, INC. do?
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases, including malignancies and autoimmune disorders, in the United States and internationally. Its lead product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), encompassing clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The company advances a pipeline featuring TG-1701, an orally available covalent Bruton's tyrosine kinase (BTK) inhibitor selective for BTK; TG-1801, a bispecific CD47 and CD19 antibody; and azer-cel, an allogeneic CD19 CAR T therapy, all targeting B-cell disorders and currently in early clinical stages. TG Therapeutics, Inc. generates revenue primarily from BRIUMVI net product sales in the U.S., with additional contributions from international partners. Founded in 1993 and headquartered in Morrisville, North Carolina, it plays a key role in addressing unmet needs in neurology and oncology through targeted immunotherapies.